Exact Sciences
EXAS
#1765
Rank
A$14.44 B
Marketcap
$78.05
Share price
-3.29%
Change (1 day)
-16.92%
Change (1 year)
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.

Exact Sciences (EXAS) - Total debt

Total debt on the balance sheet as of September 2024 : A$4.18 Billion

According to Exact Sciences's latest financial reports the company's total debt is A$4.18 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exact Sciences - Total debt on balance sheet (from 2009 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$3.74 B4.29%
2022-12-31A$3.59 B9.43%
2021-12-31A$3.28 B8.41%
2020-12-31A$3.03 B122.21%
2019-12-31A$1.36 B39.42%
2018-12-31A$0.97 B17060.9%
2017-12-31A$5.7 M-25.18%
2016-12-31A$7.62 M-7.72%
2015-12-31A$8.25 M127.25%
2014-12-31A$3.63 M-25.76%
2013-12-31A$4.89 M148.85%
2012-12-31A$1.96 M101.68%
2011-12-31A$0.97 M-0.93%
2010-12-31A$0.98 M-55.52%
2009-12-31A$2.21 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
A$0.21 B-94.80%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
A$29.85 M-99.29%๐Ÿ‡บ๐Ÿ‡ธ USA
A$17.57 M-99.58%๐Ÿ‡บ๐Ÿ‡ธ USA
A$38.60 B 823.03%๐Ÿ‡ซ๐Ÿ‡ท France